Chemotherapy-induced peripheral neuropathy is a severe clinical problem frequently
associated with cisplatin use. Although its pathophysiology is poorly understood, it is known …

Cisplatin is the preferential chemotherapeutic drug for highly prevalent solid tumours.
However, its clinical efficacy is frequently limited due to neurotoxic effects such as peripheral …

BACKGROUND AND PURPOSE In the current study, we investigated the role of both kinin
B1 and B2 receptors in peripheral neuropathy induced by the chronic treatment of mice with …

Abstract Kinin B 1 (B 1 R) and B 2 receptors (B 2 R) and the transient receptor potential
vanilloid 4 (TRPV4) channel are known to play a critical role in the peripheral neuropathy …

Chemotherapy-induced peripheral neuropathy is a frequent, disabling side effect of
anticancer drugs. Oxaliplatin, a platinum compound used in the treatment of advanced …

Carboplatin, an anticancer drug, often causes chemotherapy-induced peripheral neuropathy
(PN). Transient receptor potential ankyrin 1 (TRPA1), a non-selective cation channel, is a …

Chemotherapy-induced peripheral neuropathy (CIPN), characterized by symptoms of
paresthesia, dysesthesia, numbness, and pain, is a common adverse effect of several …

Paclitaxel is a chemotherapeutic agent used to treat solid tumours. However, it causes an
acute and neuropathic pain syndrome that limits its use. Among the mechanisms involved in …

Chemotherapy-induced peripheral neuropathy (CIPN) is a severe and painful adverse
reaction of cancer treatment in patients that is little understood or treated. Cytotoxic drugs …

Background Paclitaxel (PCX) is the first‐line choice for the treatment of several types of
cancer, including breast, ovarian, and lung cancers. However, patients who receive even a …